PRQR ProQR Therapeutics N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 15.91M | 18.91M |
| R&D expense | 44.73M | 36.36M |
| SG&A expense | 15.06M | 13.66M |
| Operating income | -43.45M | -30.47M |
| Interest expense | 929,000 | 1.08M |
| Pretax income | -42.16M | -27.96M |
| Income tax | 19,000 | -197,000 |
| Net income | -42.18M | -27.76M |
| EPS (basic) | -0.40 | -0.32 |
| EPS (diluted) | -0.40 | -0.32 |
| Weighted avg. shares (diluted) | 105.33M | 86.09M |
| Balance sheet | ||
| Cash & equivalents | 92.41M | 149.41M |
| Receivables | 6.80M | 3.75M |
| Current assets | 100.13M | 153.84M |
| PP&E, netmay include right-of-use assets (IFRS) | 12.63M | 14.11M |
| Total assets | 112.76M | 167.96M |
| Current liabilities | 32.44M | 38.90M |
| Short-term debt | 4.87M | 4.58M |
| Total liabilities | 63.38M | 79.40M |
| Shareholders' equity | 49.37M | 88.56M |
| Cash flow statement | ||
| Operating cash flow | -52.79M | -36.39M |
| Capital expenditure | 1.02M | 1.42M |
| Free cash flow | -53.81M | -37.81M |
| Investing cash flow | -1.02M | -4.07M |
| Financing cash flow | -1.84M | 70.28M |
| Stock-based compensation | 4.01M | 2.54M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.